Regeneron Pharmaceuticals Inc (REGN) EVP Neil Stahl Sells 9,853 Shares

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) EVP Neil Stahl sold 9,853 shares of the firm’s stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $305.74, for a total transaction of $3,012,456.22. Following the completion of the transaction, the executive vice president now directly owns 47,450 shares of the company’s stock, valued at approximately $14,507,363. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

REGN stock opened at $304.94 on Friday. Regeneron Pharmaceuticals Inc has a 12-month low of $291.10 and a 12-month high of $442.00. The company has a debt-to-equity ratio of 0.08, a current ratio of 4.58 and a quick ratio of 3.78. The company has a market capitalization of $33.32 billion, a price-to-earnings ratio of 15.40, a P/E/G ratio of 1.44 and a beta of 1.08.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Tuesday, May 7th. The biopharmaceutical company reported $4.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.24 by ($0.79). The company had revenue of $1.71 billion during the quarter, compared to analysts’ expectations of $1.76 billion. Regeneron Pharmaceuticals had a return on equity of 26.95% and a net margin of 35.13%. The firm’s quarterly revenue was up 13.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $4.67 EPS. On average, research analysts expect that Regeneron Pharmaceuticals Inc will post 18.37 earnings per share for the current fiscal year.

A number of equities analysts recently commented on the stock. ValuEngine lowered shares of Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, May 13th. Cantor Fitzgerald decreased their price objective on shares of Regeneron Pharmaceuticals from $441.00 to $405.00 and set a “neutral” rating for the company in a research note on Monday, May 13th. BMO Capital Markets decreased their price objective on shares of Regeneron Pharmaceuticals from $412.00 to $375.00 and set a “market perform” rating for the company in a research note on Wednesday, May 8th. Morgan Stanley cut their target price on shares of Regeneron Pharmaceuticals from $420.00 to $389.00 and set an “equal weight” rating for the company in a research report on Wednesday, May 8th. Finally, Canaccord Genuity reiterated a “hold” rating and issued a $353.00 target price (down previously from $408.00) on shares of Regeneron Pharmaceuticals in a research report on Wednesday, May 8th. Three equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Regeneron Pharmaceuticals presently has an average rating of “Hold” and an average target price of $404.88.

Several institutional investors have recently added to or reduced their stakes in the company. Joel Isaacson & Co. LLC raised its holdings in shares of Regeneron Pharmaceuticals by 0.8% during the 1st quarter. Joel Isaacson & Co. LLC now owns 3,042 shares of the biopharmaceutical company’s stock valued at $1,249,000 after purchasing an additional 25 shares in the last quarter. Diversified Trust Co raised its holdings in shares of Regeneron Pharmaceuticals by 0.8% during the 4th quarter. Diversified Trust Co now owns 3,630 shares of the biopharmaceutical company’s stock valued at $1,356,000 after purchasing an additional 30 shares in the last quarter. Cornerstone Advisors Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 3.7% during the 1st quarter. Cornerstone Advisors Inc. now owns 842 shares of the biopharmaceutical company’s stock valued at $346,000 after purchasing an additional 30 shares in the last quarter. Comprehensive Portfolio Management LLC raised its holdings in shares of Regeneron Pharmaceuticals by 4.1% during the 1st quarter. Comprehensive Portfolio Management LLC now owns 833 shares of the biopharmaceutical company’s stock valued at $342,000 after purchasing an additional 33 shares in the last quarter. Finally, Kaizen Advisory LLC raised its holdings in shares of Regeneron Pharmaceuticals by 21.2% during the 4th quarter. Kaizen Advisory LLC now owns 200 shares of the biopharmaceutical company’s stock valued at $75,000 after purchasing an additional 35 shares in the last quarter. Institutional investors and hedge funds own 67.63% of the company’s stock.

WARNING: This piece was originally reported by Baseball Daily News and is owned by of Baseball Daily News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece can be viewed at https://www.baseballdailydigest.com/news/2019/05/18/regeneron-pharmaceuticals-inc-regn-evp-neil-stahl-sells-9853-shares.html.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Featured Story: What strategies should day traders use to execute a trade?

Insider Buying and Selling by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.